PULSE BIOSCIENCES, INC.(PLSE)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,864 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
PLSE Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for PULSE BIOSCIENCES, INC. (PLSE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PLSE at 14.4/100 on a 32-signal composite quality model, placing it at rank #2,864 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), PULSE BIOSCIENCES, INC. reports quarterly revenue of $434.0K, net income of $-24.7M, free cash flow of $-18.8M. Top institutional holders of PLSE by reported 13-F value include BlackRock, BANK OF AMERICA, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. PLSE trades on the Nasdaq exchange and files with the SEC under CIK 1625101. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PLSE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PULSE BIOSCIENCES, INC. directly from SEC EDGAR. PULSE BIOSCIENCES, INC.'s 13F Pro composite quality score has ranged between 12 and 16 since 2026, currently 14.4 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.
Revenue
Q2 2026
$434.0K
Net Income
Q2 2026
$-24.7M
Free Cash Flow
Q2 2026
$-18.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-35.8% YoYOperating Income
-36.8% YoYTotal Assets
-28.6% YoYOp. Cash Flow
-48.9% YoYFree Cash Flow
-49.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $350.0K | $0.00 | $0.00 -100.0% | $700.0K -50.6% | $1.4M | $0.00 |
| Net Income | $-72.8M -35.8% | $-53.6M -26.9% | $-42.2M +27.9% | $-58.5M +8.1% | $-63.7M -27.7% | $-49.9M |
| Operating Income | $-76.9M -36.8% | $-56.3M -29.1% | $-43.6M +24.9% | $-58.1M +7.9% | $-63.0M -26.1% | $-50.0M |
| Total Assets | $94.5M -28.6% | $132.5M +123.9% | $59.2M -24.0% | $77.9M +31.7% | $59.2M +43.3% | $41.3M |
| Operating Cash Flow | $-54.1M -48.9% | $-36.3M -10.0% | $-33.0M +29.7% | $-47.0M +13.1% | $-54.1M -53.0% | $-35.4M |
| Free Cash Flow | $-54.4M -49.3% | $-36.5M -10.0% | $-33.2M +30.1% | $-47.4M +13.1% | $-54.5M -52.3% | $-35.8M |
Get alerted when PLSE's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for PULSE BIOSCIENCES, INC. including:
Top Institutional Holders of PLSE
BlackRock, Inc.
$40.7M1,466,702 shBANK OF AMERICA CORP /DE/
$40.1M1,446,611 shVANGUARD CAPITAL MANAGEMENT LLC
$21.9M788,640 shPortolan Capital Management, LLC
$20.9M753,333 shPRICE T ROWE ASSOCIATES INC /MD/
$20.8M748,638 shBALYASNY ASSET MANAGEMENT L.P.
$19.9M718,103 shCITADEL ADVISORS LLC
$17.4M626,514 shGEODE CAPITAL MANAGEMENT, LLC
$14.9M536,276 shSTATE STREET CORP
$14.7M529,624 shMASSACHUSETTS FINANCIAL SERVICES CO /MA/
$12.8M462,734 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $40.7M | 1,466,702 |
| BANK OF AMERICA CORP /DE/ | $40.1M | 1,446,611 |
| VANGUARD CAPITAL MANAGEMENT LLC | $21.9M | 788,640 |
| Portolan Capital Management, LLC | $20.9M | 753,333 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $20.8M | 748,638 |
| BALYASNY ASSET MANAGEMENT L.P. | $19.9M | 718,103 |
| CITADEL ADVISORS LLC | $17.4M | 626,514 |
| GEODE CAPITAL MANAGEMENT, LLC | $14.9M | 536,276 |
| STATE STREET CORP | $14.7M | 529,624 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $12.8M | 462,734 |
More Healthcare Companies
View all Healthcare →Put PLSE on your watchlist
Track score changes the day PULSE BIOSCIENCES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PLSE a good stock to buy?
13F Pro's AI-powered analysis of PULSE BIOSCIENCES, INC. (PLSE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PLSE are available on the PLSE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PLSE is classified as a mid company.
Which hedge funds own PLSE?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PLSE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PULSE BIOSCIENCES, INC.'s investment landscape.